Praluent

Aug 07, 2026

Summary For nearly a decade, PCSK9 inhibitors have been highly effective at lowering LDL cholesterol, but their growth has been limited by the need for injections. The U.S. FDA approval of Merck’s LIPFENDRA (enlicitide) changes that by introducing the first oral PCSK9 inhibitor, marking a major shift from ne...

Apr 30, 2019

A Praluent boost for Sanofi, and Regeneron The U.S. FDA has given its nod to Praluent (alirocumab) to be used for reducing the risk of heart attack, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular (CV) disease. Praluent is an injectable prescription medicine co-dev...

Mar 14, 2018

Sanofi and Regeneron Pharmaceuticals got effective results in reducing the risk of major adverse heart events in a clinical study of nearly 19,000 patients with the help of cholesterol drug Praluent. Drugmakers now hope that the results are good enough to convince insurers to pay for the pricey medicine. Treatment w...